Analyst Rating Update on Novavax (NVAX)

Novavax (NVAX) : 5 brokerage houses believe that Novavax (NVAX) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Novavax (NVAX). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 6 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.33.

Novavax (NVAX) : 6 Wall Street analysts covering Novavax (NVAX) believe that the average level the stock could reach for the short term is $13.15. The maximum price target given is $17 and the minimum target for short term is around $6, hence the standard deviation is calculated at $3.81.

For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Citigroup maintains its rating on Novavax (NASDAQ:NVAX). As per the latest information, the brokerage house raises the price target to $12 per share from a prior target of $10. The shares have been rated Buy. The rating by the firm was issued on July 28, 2016.


Novavax (NASDAQ:NVAX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.22 and $7.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.65. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.61, notching a gain of 5.84% for the day. The total traded volume was 4,317,570 . The stock had closed at $7.19 on the previous day.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.